The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...

Novo Nordisk said Jørgensen will remain in his role temporarily to ensure a “smooth transition” while a search for his ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down after eight years at the helm, as the Danish pharmaceutical giant ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

Novo Nordisk's share price has taken a battering over the past year amid increased competition in the ballooning obesity drug ...

Not all is lost, and there are additional efforts the company is making to stay relevant, ranging from new trials of CagriSema and higher doses of semaglutide, to external innovation. NVO remains ...

A key reason for NVO's drop is the disappointing trial results for its obesity and diabetes treatment CagriSema. The first big price fall came after the company released its phase 3 trial results ...